Immunoallergic Drug-Induced Liver Injury in Humans

ABSTRACT

No conclusive data exist that define the mechanisms of idiosyncratic drug-induced liver injury (DILI) in humans; therefore, we are forced to speculate based on their clinical characteristics. The major characteristics are most easily explained by an immune mechanism. Many cases of idiosyncratic DILI tend to have a longer delay in onset and sometimes do not occur rapidly on rechallenge. These instances of DILI have been attributed to metabolic idiosyncrasy. However, these characteristics may also reflect an autoimmune mechanism, and most drugs that cause idiosyncratic DILI are also associated with various types of other autoimmune reactions. A characteristic feature of the immune system is that different individuals respond differently to the same immunogen. In some cases, a drug can induce an immune response to a reactive metabolite acting as a hapten; in others, the response is against a native protein, which leads to an autoimmune reaction. This is likely responsible for the interindividual differences in susceptibility and outcome noted in human DILI.

KEYWORDS

Hepatitis - autoimmunity - idiosyncratic drug reaction - metabolic idiosyncrasy

REFERENCES

• 1 Ostapowicz G, Fontana R J, Schiødt F V U.S. Acute Liver Failure Study Group et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States.  Ann Intern Med. 2002;  137(12) 947-954
• 2 Watkins P B, Kaplowitz N, Slattery J T et al.. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial.  JAMA. 2006;  296(1) 87-93
• 3 Park B K, Kitteringham N R, Maggs J L, Pirmohamed M, Williams D P. The role of metabolic activation in drug-induced hepatotoxicity.  Annu Rev Pharmacol Toxicol. 2005;  45 177-202
• 4 Walgren J L, Mitchell M D, Thompson D C. Role of metabolism in drug-induced idiosyncratic hepatotoxicity.  Crit Rev Toxicol. 2005;  35(4) 325-361
• 5 Lerch M, Pichler W J. The immunological and clinical spectrum of delayed drug-induced exanthems.  Curr Opin Allergy Clin Immunol. 2004;  4(5) 411-419
• 6 Roujeau J C. Immune mechanisms in drug allergy.  Allergol Int. 2006;  55(1) 27-33
• 7 Martin A M, Nolan D, Gaudieri S et al.. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant.  Proc Natl Acad Sci U S A. 2004;  101(12) 4180-4185
• 8 Warkentin T E. Heparin-induced thrombocytopenia: pathogenesis and management.  Br J Haematol. 2003;  121(4) 535-555
• 9 Petz L D. Drug-induced autoimmune hemolytic anemia.  Transfus Med Rev. 1993;  7(4) 242-254
• 10 Young N S, Scheinberg P, Calado R T. Aplastic anemia.  Curr Opin Hematol. 2008;  15(3) 162-168
• 11 Roth R A, Luyendyk J P, Maddox J F, Ganey P E. Inflammation and drug idiosyncrasy—is there a connection?.  J Pharmacol Exp Ther. 2003;  307(1) 1-8
• 12 Zimmerman H. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver 2nd ed. Philadelphia, PA; Lippincott Williams & Wilkins 1999
• 13 Huang Y S, Chern H D, Su W J et al.. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis.  Hepatology. 2002;  35(4) 883-889
• 14 Lawrenson R A, Seaman H E, Sundström A, Williams T J, Farmer R D. Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data.  Drug Saf. 2000;  23(4) 333-349
• 15 Uetrecht J. Idiosyncratic drug reactions: current understanding.  Annu Rev Pharmacol Toxicol. 2007;  47 513-539
• 16 Tostmann A, Boeree M J, Aarnoutse R E, de Lange W C, van der Ven A J, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review.  J Gastroenterol Hepatol. 2008;  23(2) 192-202
• 17 Kindmark A, Jawaid A, Harbron C G et al.. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis.  Pharmacogenomics J. 2008;  8(3) 186-195
• 18 Andrade R J, Lucena M I, Alonso A et al.. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease.  Hepatology. 2004;  39(6) 1603-1612
• 19 Ungo J R, Jones D, Ashkin D et al.. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus.  Am J Respir Crit Care Med. 1998;  157(6 Pt 1) 1871-1876
• 20 Clay K D, Hanson J S, Pope S D, Rissmiller R W, Purdum III P P, Banks P M. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review.  Ann Intern Med. 2006;  144(6) 415-420
• 21 Zimpfer A, Propst A, Mikuz G, Vogel W, Terracciano L, Stadlmann S. Ciprofloxacin-induced acute liver injury: case report and review of literature.  Virchows Arch. 2004;  444(1) 87-89
• 22 Bougie D W, Wilker P R, Wuitschick E D et al.. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa.  Blood. 2002;  100(6) 2071-2076
• 23 Thiim M, Friedman L S. Hepatotoxicity of antibiotics and antifungals.  Clin Liver Dis. 2003;  7(2) 381-399, vi–vii
• 24 Elkayam O, Yaron M, Caspi D. Minocycline-induced autoimmune syndromes: an overview.  Semin Arthritis Rheum. 1999;  28(6) 392-397
• 25 Uetrecht J P, Woosley R L. Acetylator phenotype and lupus erythematosus.  Clin Pharmacokinet. 1981;  6(2) 118-134
• 26 Black M, Mitchell J R, Zimmerman H J, Ishak K G, Epler G R. Isoniazid-associated hepatitis in 114 patients.  Gastroenterology. 1975;  69(2) 289-302
• 27 Chalasani N, Fontana R J, Bonkovsky H L Drug Induced Liver Injury Network (DILIN) et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.  Gastroenterology. 2008;  135(6) 1924-1934, 1934, e1–e4
• 28 Keisu M, Andersson T B. Drug-induced liver injury in humans: the case of ximelagatran. In: Uetrecht JP Mechanisms of Adverse Drug Reactions. Heidelberg, Germany; Springer-Verlag In press
• 29 Polak B CP, Wesseling H, Schut D, Herxheimer A, Meyler L. Blood dyscrasias attributed to chloramphenicol. A review of 576 published and unpublished cases.  Acta Med Scand. 1972;  192(5) 409-414
• 30 Keohane E M. Acquired aplastic anemia.  Clin Lab Sci. 2004;  17(3) 165-171
• 31 Waldhauser L, Uetrecht J. Antibodies to myeloperoxidase in propylthiouracil-induced autoimmune disease in the cat.  Toxicology. 1996;  114(2) 155-162
• 32 Lawson T M, Amos N, Bulgen D, Williams B D. Minocycline-induced lupus: clinical features and response to rechallenge.  Rheumatology (Oxford). 2001;  40(3) 329-335
• 33 Warkentin T E, Kelton J G. Temporal aspects of heparin-induced thrombocytopenia.  N Engl J Med. 2001;  344(17) 1286-1292
• 34 Maddrey W C, Boitnott J K. Isoniazid hepatitis.  Ann Intern Med. 1973;  79(1) 1-12
• 35 Tahaoğlu K, Ataç G, Sevim T et al.. The management of anti-tuberculosis drug-induced hepatotoxicity.  Int J Tuberc Lung Dis. 2001;  5(1) 65-69
• 36 Pellock J M. Felbamate.  Epilepsia. 1999;  40(Suppl 5) S57-S62
• 37 Bourdi M, Chen W, Peter R M et al.. Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis.  Chem Res Toxicol. 1996;  9(7) 1159-1166
• 38 Martin J L, Kenna J G, Martin B M, Thomassen D, Reed G F, Pohl L R. Halothane hepatitis patients have serum antibodies that react with protein disulfide isomerase.  Hepatology. 1993;  18(4) 858-863
• 39 Watkins P B. Idiosyncratic liver injury: challenges and approaches.  Toxicol Pathol. 2005;  33(1) 1-5
• 40 Eksteen B, Afford S C, Wigmore S J, Holt A P, Adams D H. Immune-mediated liver injury.  Semin Liver Dis. 2007;  27(4) 351-366
• 41 Manns M P, Vogel A. Autoimmune hepatitis, from mechanisms to therapy.  Hepatology. 2006;  43(2, Suppl 1) S132-S144
• 42 Rotmensch H H, Yust I, Siegman-Igra Y, Liron M, Ilie B, Vardinon N. Granulomatous hepatitis: a hypersensitivity response to procainamide.  Ann Intern Med. 1978;  89(5 Pt 1) 646-647
• 43 Lewis J H, Zimmerman H J, Benson G D, Ishak K G. Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases.  Gastroenterology. 1984;  86(3) 503-513
• 44 Salazar-Páramo M, Rubin R L, García-De La Torre I. Systemic lupus erythematosus induced by isoniazid.  Ann Rheum Dis. 1992;  51(9) 1085-1087
• 45 Gough A, Chapman S, Wagstaff K, Emery P, Elias E. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome.  BMJ. 1996;  312(7024) 169-172
• 46 Dupont A, Six R. Lupus-like syndrome induced by methyldopa.  Br Med J (Clin Res Ed). 1982;  285(6343) 693-694
• 47 Liu Z X, Kaplowitz N. Immune-mediated drug-induced liver disease.  Clin Liver Dis. 2002;  6(3) 455-474
• 48 Murphy W G, Kelton J G. Methyldopa-induced autoantibodies against red blood cells.  Blood Rev. 1988;  2(1) 36-42
• 49 Perry Jr H M. Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis.  Am J Med. 1973;  54(1) 58-72
• 50 Selroos O, Edgren J. Lupus-like syndrome associated with pulmonary reaction to nitrofurantoin. Report of three cases.  Acta Med Scand. 1975;  197(1-2) 125-129
• 51 Sharp J R, Ishak K G, Zimmerman H J. Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin.  Ann Intern Med. 1980;  92(1) 14-19
• 52 Levy M. Propylthiouracil hepatotoxicity. A review and case presentation.  Clin Pediatr (Phila). 1993;  32(1) 25-29
• 53 Takuwa N, Kojima I, Ogata E. Lupus-like syndrome—a rare complication in thionamide treatment for Graves' disease.  Endocrinol Jpn. 1981;  28(5) 663-667
• 54 Kurtz M D. Migratory polyarthritis occurring with methimazole therapy.  N Y State J Med. 1968;  68 2810-2811
• 55 Fischer M G, Nayer H R, Miller A. Methimazole-induced jaundice.  JAMA. 1973;  223(9) 1028-1029
• 56 McCraken M, Benson E A, Hickling P. Systemic lupus erythematosus induced by aminoglutethimide.  BMJ. 1980;  281(6250) 1254
• 57 Stuart-Harris R C, Smith I E. Aminoglutethimide in the treatment of advanced breast cancer.  Cancer Treat Rev. 1984;  11 189-204
• 58 Kramer M R, Levene C, Hershko C. Severe reversible autoimmune haemolytic anaemia and thrombocytopenia associated with diclofenac therapy.  Scand J Haematol. 1986;  36(1) 118-120
• 59 Scully L J, Clarke D, Barr R J. Diclofenac induced hepatitis. 3 cases with features of autoimmune chronic active hepatitis.  Dig Dis Sci. 1993;  38(4) 744-751
• 60 Choi H K, Merkel P A, Niles J L. ANCA-positive vasculitis associated with allopurinol therapy.  Clin Exp Rheumatol. 1998;  16(6) 743-744
• 61 Chawla S K, Patel H D, Parrino G R, Soterakis J, Lopresti P A, D'Angelo W A. Allopurinol hepatotoxicity. Case report and literature review.  Arthritis Rheum. 1977;  20(8) 1546-1549
• 62 Ecker J A. Phenylbutazone hepatitis.  Am J Gastroenterol. 1965;  43 23-29
• 63 Farid N, Anderson J. S.L.E.-like reaction after phenylbutazone.  Lancet. 1971;  1(7707) 1022-1023
• 64 Brown M, Schubert T. Phenytoin hypersensitivity hepatitis and mononucleosis syndrome.  J Clin Gastroenterol. 1986;  8(4) 469-477
• 65 Ross S, Ormerod A D, Roberts C, Dwyer C, Herriot R. Subacute cutaneous lupus erythematosus associated with phenytoin.  Clin Exp Dermatol. 2002;  27(6) 474-476
• 66 Bateman D E. Carbamazepine induced systemic lupus erythematosus: case report.  Br Med J (Clin Res Ed). 1985;  291(6496) 632-633
• 67 Morales-Diaz M, Pinilla-Roa E, Ruiz I. Suspected carbamazepine-induced hepatotoxicity.  Pharmacotherapy. 1999;  19(2) 252-255
• 68 Dujovne C A, Chan C H, Zimmerman H J. Sulfonamide hepatic injury. Review of the literature and report of a case due to sulfamethoxazole.  N Engl J Med. 1967;  277(15) 785-788
• 69 Hoffman B J. Sensitivity to sulfadiazine resembling acute lupus erythematosus.  Arch Dermatol Syph. 1945;  51 190-192
• 70 Alberti-Flor J J. Chlorpromazine-induced lupus-like illness.  Am Fam Physician. 1983;  27(4) 151-152
• 71 Russell R I, Allan J G, Patrick R. Active chronic hepatitis after chlorpromazine ingestion.  BMJ. 1973;  1(5854) 655-656
• 72 Bonsmann G, Schiller M, Luger T A, Ständer S. Terbinafine-induced subacute cutaneous lupus erythematosus.  J Am Acad Dermatol. 2001;  44(6) 925-931
• 73 Fernandes N F, Geller S A, Fong T L. Terbinafine hepatotoxicity: case report and review of the literature.  Am J Gastroenterol. 1998;  93(3) 459-460
• 74 Ahmad S. Lovastatin-induced lupus erythematosus.  Arch Intern Med. 1991;  151(8) 1667-1668
• 75 Alla V, Abraham J, Siddiqui J et al.. Autoimmune hepatitis triggered by statins.  J Clin Gastroenterol. 2006;  40(8) 757-761
• 76 Marzano A V, Ramoni S, Del Papa N, Barbareschi M, Alessi E. Leflunomide-induced subacute cutaneous lupus erythematosus with erythema multiforme-like lesions.  Lupus. 2008;  17(4) 329-331
• 77 Sevilla-Mantilla C, Ortega L, Agúndez J A, Fernández-Gutiérrez B, Ladero J M, Díaz-Rubio M. Leflunomide-induced acute hepatitis.  Dig Liver Dis. 2004;  36(1) 82-84
• 78 Actis G C, Morgando A, Lagget M, David E, Rizzetto M. Zafirlukast-related hepatitis: report of a further case.  J Hepatol. 2001;  35(4) 539-541
• 79 Finkel T H, Hunter D J, Paisley J E, Finkel R S, Larsen G L. Drug-induced lupus in a child after treatment with zafirlukast (Accolate).  J Allergy Clin Immunol. 1999;  103(3 Pt 1) 533-534
• 80 Soy M, Ozer H, Canataroglu A, Gumurdulu D, Erken E. Vasculitis induced by zafirlukast therapy.  Clin Rheumatol. 2002;  21(4) 328-329
• 81 Mizutani T, Shinoda M, Tanaka Y et al.. Autoantibodies against CYP2D6 and other drug-metabolizing enzymes in autoimmune hepatitis type 2.  Drug Metab Rev. 2005;  37(1) 235-252
• 82 Uetrecht J P. Drug metabolism by leukocytes, its role in drug-induced lupus and other idiosyncratic drug reactions.  Crit Rev Toxicol. 1990;  20(4) 213-235
• 83 Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies.  Lancet. 2006;  368(9533) 404-418
• 84 Bowen D G, McCaughan G W, Bertolino P. Intrahepatic immunity: a tale of two sites?.  Trends Immunol. 2005;  26(10) 512-517
• 85 Séguin B, Uetrecht J. The danger hypothesis applied to idiosyncratic drug reactions.  Curr Opin Allergy Clin Immunol. 2003;  3(4) 235-242
• 86 Uetrecht J. Current trends in drug-induced autoimmunity.  Autoimmun Rev. 2005;  4(5) 309-314
• 87 Vergani D, Mieli-Vergani G. Aetiopathogenesis of autoimmune hepatitis.  World J Gastroenterol. 2008;  14(21) 3306-3312
• 88 Sayeh E, Uetrecht J P. Factors that modify penicillamine-induced autoimmunity in Brown Norway rats: failure of the Th1/Th2 paradigm.  Toxicology. 2001;  163(2-3) 195-211
• 89 Fouser L A, Wright J F, Dunussi-Joannopoulos K, Collins M. Th17 cytokines and their emerging roles in inflammation and autoimmunity.  Immunol Rev. 2008;  226 87-102
• 90 Diveu C, McGeachy M J, Cua D J. Cytokines that regulate autoimmunity.  Curr Opin Immunol. 2008;  20(6) 663-668
• 91 Roark C L, Simonian P L, Fontenot A P, Born W K, O'Brien R L. Gammadelta T cells: an important source of IL-17.  Curr Opin Immunol. 2008;  20(3) 353-357